Legalize59765 laws
59765 laws
- § 356g. Standards for regenerative medicine and regenerative advanced therapies
- § 356j. Discontinuance or interruption in the production of medical devices
- § 356l. Advanced manufacturing technologies designation program
- § 356–1. Accelerated approval of priority countermeasures
- § 356–2. Accelerated approval Council
- § 357. Qualification of drug development tools
- § 358. Authority to designate official names
- § 360bbb–5. Critical Path Public-Private Partnerships
- § 360bbb–5a. Emerging technology program
- § 360bbb–6. Risk communication
- § 360bbb–7. Notification
- § 384g. Restricting entrance of illicit drugs
- § 360bbb–8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments
- § 360bbb–8a. Optimizing global clinical trials
- § 360bbb–8b. Use of clinical investigation data from outside the United States
- § 360bbb–8c. Patient participation in medical product discussion
- § 360eee–3. National standards for third-party logistics providers
- § 360eee–4. Uniform national policy
- § 360ee–1. FDA rare neurodegenerative disease grant program
- § 360e–1. Pediatric uses of devices
- § 360e–3. Breakthrough devices
- § 1435. Delegation of authority by Secretary
- § 360ff. Priority review to encourage treatments for rare pediatric diseases
- § 360fff. Definitions
- § 360fff–1. Submission of requests
- § 360fff–2. Eligibility determinations; data submission; filing
- § 360fff–3. GRASE determination
- § 360hh. Definitions
- § 360h–1. Program to improve the device recall system
- § 360i. Records and reports on devices
- § 360ii. Program of control
- § 360j. General provisions respecting control of devices intended for human use
- § 360jj. Studies by Secretary
- § 360k. State and local requirements respecting devices
- § 360kk. Performance standards for electronic products
- § 364b. Good manufacturing practice
- § 364c. Registration and product listing
- § 364d. Safety substantiation
- § 364e. Labeling
- § 364f. Records
- § 364g. Mandatory recall authority
- § 364h. Small businesses
- § 364i. Exemption for certain products and facilities
- § 364j. Preemption
- § 371. Regulations and hearings
- § 372. Examinations and investigations
- § 372a. Transferred
- § 379j–12. Authority to assess and use animal drug fees
- § 379j–13. Reauthorization; reporting requirements
- § 379j–21. Authority to assess and use generic new animal drug fees